Brief: Cspc Pharmaceutical's Recombinant Herpes Zoster Vaccine (Sys6052) Obtains FDA Clinical Trial Approval In U.S.
29/09/2026 11:07
BRIEF-Cspc Pharmaceutical's Recombinant Herpes Zoster Vaccine (Sys6052) Obtains FDA Clinical Trial Approval In U.S. Sept 29 (Reuters) - CSPC PHARMACEUTICAL GROUP LIMITED 1093.HK:
PHARMA'S RECOMBINANT HERPES ZOSTER VACCINE (SYS6052) OBTAINS FDA CLINICAL TRIAL APPROVAL IN U.S.
Further company coverage: 1093.HK
((reuters.briefs@thomsonreuters.com))
Recent news on CSPC PHARMACEUTICAL
See all newsBrief: CSPC Pharmaceutical Posts CSPC Innovation Pharmaceutical 9M Net Profit Attributable RMB 1.21 Billion
Brief: CSPC Pharmaceutical Publishes Updated Phase III OS Results For Anbenitamab In Her2-Positive Advanced Gastric Cancer
Brief: CSPC Pharmaceutical Says Batoclimab Injection (Enlida) Obtains Drug Registration Certificate From NMPA
Brief: CSPC Pharmaceutical Initiates Phase III Trial Of SYS6043 For Triple-Negative Breast Cancer In China
Factbox: Pharma sector doubles down on AI to slash costs, timelines